NEW YORK (GenomeWeb) – Belgian molecular diagnostics developer MDxHealth announced today that its ConfirmMDx prostate cancer test has been included as an in-network benefit under the California Medical Assistance Program (Medi-Cal).
Medi-Cal is California's state-run Medicaid program and has approximately 12 million enrollees. With the inclusion of ConfirmMDx in the program, MDxHealth said it will seek access to the test through other US Medicaid programs.
"This agreement provides a model for further expansion of coverage in the US as health providers increasingly recognize the ability of ConfirmMDx to improve patient outcomes and help manage rising healthcare costs," MDxHealth CEO Jan Groen said in a statement.
The Medi-Cal approval marks the latest in a series of positive coverage decisions MDxHealth has received for ConfirmMDx recently. Last month, Cigna issued a positive medical policy decision for the test, and in June the company announced the test would be covered by Michigan-based health plan Priority Health.